Hötker Andreas M, Mazaheri Yousef, Zheng Junting, Moskowitz Chaya S, Berkowitz Joshua, Lantos Joshua E, Pei Xin, Zelefsky Michael J, Hricak Hedvig, Akin Oguz
Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA,
Eur Radiol. 2015 Sep;25(9):2665-72. doi: 10.1007/s00330-015-3688-1. Epub 2015 Mar 29.
To investigate the effects of androgen-deprivation therapy (ADT) on MRI parameters and evaluate their associations with treatment response measures.
The study included 30 men with histopathologically confirmed prostate cancer who underwent MRI before and after initiation of ADT. Thirty-four tumours were volumetrically assessed on DW-MRI (n = 32) and DCE-MRI (n = 18), along with regions of interest in benign prostatic tissue, to calculate apparent diffusion coefficient (ADC) and transfer constant (K(trans)) values. Changes in MRI parameters and correlations with clinical parameters (change in prostate-specific antigen [PSA], treatment duration, PSA nadir) were assessed.
Prostate volume and PSA values decreased significantly with therapy (p < 0.001). ADC values increased significantly in tumours and decreased in benign prostatic tissue (p < 0.05). Relative changes in ADC and absolute post-therapeutic ADC values differed significantly between tumour and benign tissue (p < 0.001). K(trans) decreased significantly only in tumours (p < 0.001); relative K(trans) changes and post-therapeutic values were not significantly different between tumour and benign tissue. The relative change in tumour ADC correlated significantly with PSA decrease. No changes were associated with treatment duration or PSA nadir.
Multi-parametric MRI shows significant measurable changes in tumour and benign prostate caused by ADT and may help in monitoring treatment response.
• Androgen-deprivation therapy caused changes of ADC, K (trans) in tumour and benign prostate. • Prostate volume and PSA values decreased significantly with therapy. • ADC values may be helpful for monitoring treatment response.
研究雄激素剥夺疗法(ADT)对磁共振成像(MRI)参数的影响,并评估其与治疗反应指标的相关性。
本研究纳入30例经组织病理学确诊的前列腺癌男性患者,在开始ADT治疗前后均接受了MRI检查。在扩散加权磁共振成像(DW-MRI,n = 32)和动态对比增强磁共振成像(DCE-MRI,n = 18)上对34个肿瘤以及良性前列腺组织的感兴趣区域进行体积评估,以计算表观扩散系数(ADC)和转移常数(K(trans))值。评估MRI参数的变化及其与临床参数(前列腺特异性抗原[PSA]变化、治疗持续时间、PSA最低点)的相关性。
治疗后前列腺体积和PSA值显著下降(p < 0.001)。肿瘤内ADC值显著升高,良性前列腺组织内ADC值下降(p < 0.05)。肿瘤组织和良性组织之间ADC的相对变化以及治疗后的绝对ADC值存在显著差异(p < 0.001)。仅肿瘤内的K(trans)显著下降(p < 0.001);肿瘤组织和良性组织之间K(trans)的相对变化和治疗后的值无显著差异。肿瘤ADC的相对变化与PSA下降显著相关。未发现与治疗持续时间或PSA最低点相关的变化。
多参数MRI显示ADT可导致肿瘤和良性前列腺组织出现显著的可测量变化,可能有助于监测治疗反应。
• 雄激素剥夺疗法导致肿瘤和良性前列腺组织的ADC、K(trans)发生变化。 • 治疗后前列腺体积和PSA值显著下降。 • ADC值可能有助于监测治疗反应。